Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
ADCC
Patented Technology Could Improve Efficacy of Monoclonal Antibodies
By HCat at 2007-02-06 10:34
 

    BioWa, Inc has a patented technology platform called Potelligent which modifies monoclonal antibodies so that they have enhanced binding to increase Antibodyterm-dependent cellular cytotoxicity (ADCC). ADCC is the mechanism by which some antibodies can kill cancer cells. Once an antibody binds to a cell, Natural Killer (NK) cells and Monocytes in the immune system attack the bound cell, ultimately killing it.

    UCB biopharmaceutical company has been has been allowed to use Potelligent in order to develop new antibodies toward novel targets. The enhanced ADCC could help bring new antibodies to market that have greater efficacy while possibly lowering production costs of the treatment. Erbituxterm and Herceptin are antibodies whose efficacy is dependent on ADCC.

read more | 2788 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 11:23 PM.